Dompé Farmaceutici S.p.A

Quick facts

Marketed products

• Ketoprofen Lysine Salt · Pain Management / Rheumatology
  Ketoprofen lysine salt is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antipyretic effects.
• Oxervate · Oncology
• OXERVATE® 0.002% · Ophthalmology
  OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy.

Phase 3 pipeline

• DFL24498 · Oncology
  DFL24498 is a tyrosine kinase inhibitor targeting specific oncogenic pathways in cancer cells.
• Libexin® · Respiratory / Pulmonology
  Libexin is a non-narcotic antitussive agent that suppresses cough by acting as a local anesthetic on the respiratory mucosa and reducing airway irritation.
• OKITASK® · Ophthalmology
  OKITASK is a topical ophthalmic agent designed to promote corneal healing and reduce inflammation in dry eye disease.

Phase 2 pipeline

• Reparixin continuous infusion
• reparixin intermittent infusion
• Repertaxin · Other
• rhNGF

Phase 1 pipeline

• Fluifort® syrup
• KSL 40 mg

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dompé Farmaceutici S.p.A portfolio CI brief
• Dompé Farmaceutici S.p.A pipeline updates RSS